October 25th – 28th, join Cyxone at Bio-Europe. The digital event designed to facilitate the flow of global life science deals.
Read More

See CEO Tara Heitner’s presentation from the Vator Securities Healthcare Summit on 7 October

Read More

CEO Tara Heitner will present at Aktiespararna’s “For Women only” on 19 October at 14.00-14.30

Read More

Cyxone – Building stronger, safer bridges to health

Treatments for diseases such as rheumatoid arthritis, multiple sclerosis and virally induced acute respiratory disorders such as Covid 19 have come a long way but still have several shortcomings. These include adverse side effects, administration forms that often require visits to the hospital, and poor response or resistance in some patients. Cyxone is a clinical-stage biotech company focusing on the development of treatments that are administered early stage, have fewer, less severe side effects, can be taken on an outpatient basis and are showing promising response in early clinical trials. To put it simply, Cyxone’s treatments will increase the quality of life for millions of people.

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More

CEO Tara Heitner comments

“Step by step we aim to become a company that is equipped to run and manage multiple drug development programs in parallel which can deliver unique solutions for patients. Together with research collaborators and strategic partners around the world, we are confident to fully deliver on the potential in our innovative pipeline.”

Read More